Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-221
Patent Number: 8,361,722
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The patent, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer Using miR-21
Patent Number: 8,361,710
Filed: March 30, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent's abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.”
Title: microRNAs Differentially Expressed in Cervical Cancer and Uses Thereof
Patent Number: 8,361,714
Filed: Sept. 12, 2008
Lead Inventor: Sylvie Beaudenon-Huibregtse, Asuragen
The invention, the patent's abstract states, “concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.”
Title: Method for Expression of Small RNA Molecules within a Cell
Patent Number: 8,361,787
Filed: June 7, 2010
Lead Inventor: Carlos Lois-Caballe, California Institute of Technology
“The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector,” the patent's abstract states. “The methods can be used to express double-stranded RNA complexes. Small interfering RNA can be expressed using the methods of the invention within a cell, which are capable of down-regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos [and] embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down-regulated.”
Title: Therapeutic Alteration of Transplantable Tissues through In Situ or Ex Vivo Exposure to RNA Interference Molecules
Patent Number: 8,361,976
Filed: July 11, 2005
Lead Inventor: Timothy Kowalik, University of Massachusetts
“The invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent to a transplantable tissue,” the patent's abstract states. “The agent may be used to minimize organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues. The RNAi agents can be delivered as naked molecules or using liposomal and other modes of delivery to transplantable tissues. Such delivery can occur via perfusion of the RNAi agent in solution through the vasculature of a whole or partial organ; or tissues including transplantable cells and cell lines may be bathed, injected, or otherwise treated with RNAi agents. Preferred transplantable tissues include, for example, pancreas, liver, kidney, heart, lung, and all cells and cell lines derived from such tissues.”
Title: Pharmaceutical Compositions for Treatment of microRNA-Related Diseases
Patent Number: 8,361,980
Filed: March 9, 2009
Lead Inventor: Sakari Kauppinen, Santaris Pharma
The invention, the patent's abstract states, “provides compositions and methods of treatment of diseases that are sensitive to drugs that down-regulate the function of microRNAs, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long-term effect of an anti-microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the ... invention relates to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.”
Title: Method for Expression of Small Antiviral RNA Molecules with Reduced Cytotoxicity within a Cell
Patent Number: 8,361,982
Filed: April 28, 2010
Lead Inventor: Carlos Lois-Caballe, California Institute of Technology
The invention, the patent's abstract states, relates to “methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. Small interfering RNA can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding [a] lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of down-regulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of down-regulating CCR5, that are relatively non-cytotoxic to cells.”
Title: Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1-Expressing Neuroendocrine Tumors
Patent Number: 8,361,983
Filed: Oct. 27, 2010
Lead Inventor: John Nemunaitis, Gradalis
The invention comprises a “bi-functional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells,” the patent's abstract states. “The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues over-expressing the PDX-1 oncogene.”
Title: Small Interfering RNAs and Methods for Prevention, Inhibition, and/or Treatment of Malignant Progression of Breast Cancer
Patent Number: 8,361,984
Filed: Feb. 14, 2011
Lead Inventor: Chia-Hwa Lee, Taipei Medical University
The invention relates to the discovery that “over-expression and activation of alpha9-nAChR are associated with tumorigenesis of breast cancer,” and comprises “small interfering RNAs to inhibit the expression of alpha9-nAChR so as to inhibit breast cancer,” the patent's abstract states.
Title: Short Hairpin RNA for Gene Knockdown of NR1 Subunit of the N-Methyl-D-Aspartate Receptor and Its Application on Pharmaceutics
Patent Number: 8,361,985
Filed: Feb. 15, 2011
Inventor: Ping-Heng Tan, I-Shou University
The patent, its abstract states, claims “a short hairpin RNA for [knocking down the] NR1 subunit of N-methyl-D-aspartate receptor.” The shRNA comprises “a first fragment sharing homologous nucleotides among the NR1 subunit of NMDA receptor; a second fragment having complementary sequence to the first fragment; and a connecting fragment having any base in repeated arrangement, and connecting to the first and second fragments.” The invention can be used to treat pathological pain, the abstract adds.
Title: Tandem siRNAs
Patent Number: 8,362,229
Filed: Feb. 8, 2007
Lead Inventor: Huseyin Aygun, Quark Pharmaceuticals
The invention provides “novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, and respiratory conditions based upon inhibition of two or more target genes,” the patent's abstract states.
Title: Nucleic Acid Molecules and Collections Thereof, Their Application, and Modification
Patent Number: 8,362,230
Filed: Jan. 10, 2007
Lead Inventor: Ronald Plasterk, Royal Netherlands Academy of Arts and Sciences
“The invention provides a method for characterizing a sample comprising nucleic acid derived from a cell,” the patent's abstract states. “The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA ... or a mammalian ortholog thereof, and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof.”
Title: RNA Interference-Mediating Small RNA Molecules
Patent Number: 8,362,231
Filed: Jan. 6, 2010
Lead Inventor: Thomas Tuschl, Max Planck Institute
“Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference,” the patent's abstract states. “Using a Drosophila in vitro system, we demonstrate that 19-23 [nucleotide] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.”
Title: SNALP Formulations Containing Antioxidants
Application Number: 20130022649
Filed: Dec. 1, 2010
Lead Inventor: Ed Yaworski, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
The invention, the patent application's abstract states, “provides methods of preventing, decreasing, or inhibiting the degradation of cationic lipids and/or active agents present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods of making these lipid particles, and methods of delivering and/or administering these lipid particles.”
Title: siRNA Targeting Beta Secretase
Application Number: 20130023446
Filed: Sept. 13, 2012
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.”
Title: Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
Application Number: 20130023577
Filed: April 9, 2012
Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals
“This invention relates to compositions containing double-stranded ribonucleic acid in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and vascular endothelial growth factor, and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer,” the patent application's abstract states.
Title: siRNA for Inhibition of c-Met Expression and Anti-Cancer Compositions Containing the Same
Application Number: 20130023578
Filed: Dec. 28, 2009
Lead Inventor: Sun-Ok Kim, Samyang Biopharmaceuticals
The invention, the patent application's abstract states, comprises “small interfering RNA that complementarily binds to a base sequence of c-Met transcript, thereby inhibiting expression of c-Met without inducing immune responses, and use of the siRNA for prevention and/or treatment of cancer. The siRNA that complementarily binds to c-Met-encoding mRNA may inhibit expression of c-Met, which is commonly over-expressed in almost all cancer cells, through RNA interference, thereby inhibiting proliferation and metastasis of cancer cells, and thus, the siRNA may be useful as an anticancer agent.”
Title: Compositions and Methods for Inhibiting Expression of XBP-1 Gene
Application Number: 20130023580
Filed: Sept. 14, 2012
Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid targeting x-box protein 1, and methods of using the dsRNA to inhibit expression of XBP-1,” the patent application's abstract states.